Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial

被引：0
|
作者：
Renata Ferrarotto
Luana G. Sousa
Yun Qing
Diana Kaya
Bettzy Stephen
Dipti Jain
Diana Bell
Shubham Pant
Apostolia M. Tsimberidou
Filip Janku
George Blumenschein
Bonnie S. Glisson
Jordi Rodon Ahnert
Sarina A. Piha-Paul
J. Jack Lee
Michael K. Wong
Charles Lu
Funda Meric-Bernstam
Aung Naing
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Thoracic/Head and Neck Medical Oncology
[2] The University of Texas MD Anderson Cancer Center,Department of Biostatistics
[3] The University of Texas MD Anderson Cancer Center,Department of Radiology
[4] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics
[5] The University of Texas MD Anderson Cancer Center,Department of Pathology
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Pembrolizumab; Checkpoint inhibitor; Rare cancers; Cutaneous squamous cell carcinoma; Skin cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4581 / 4591
页数：10
相关论文
共 50 条
  • [31] CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC).
    Maubec, Eve
    Helfen, Sabine
    Scheer-Senyarich, Isabelle
    Boubaya, Marouane
    Schischmanoff, Olivier
    Alloux, Celine
    Deschamps, Lydia
    Petrow, Peter
    Lopez, Isabelle
    Tibi, Annick
    Levy, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] A Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Endometrial Carcinoma
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina
    Stepan, Daniel
    Li, Di
    Schmidt, Emmett
    Shumaker, Robert
    Young, Louise
    Taylor, Matthew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 152 - 153
  • [33] Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix - A gynecologic oncology group study
    Garcia, Agustin A.
    Blessing, John A.
    Vaccarello, Luis
    Roman, Lynda D.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (04): : 428 - 431
  • [34] Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
    Hughes, B. G. M.
    Munoz-Couselo, E.
    Mortier, L.
    Bratland, A.
    Gutzmer, R.
    Roshdy, O.
    Mendoza, R. Gonzalez
    Schachter, J.
    Arance, A.
    Grange, F.
    Meyer, N.
    Joshi, A.
    Billan, S.
    Zhang, P.
    Gumuscu, B.
    Swaby, R. F.
    Grob, J. -j.
    ANNALS OF ONCOLOGY, 2021, 32 (10) : 1276 - 1285
  • [35] Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial
    Migden, M. R.
    Rischin, D.
    Hudgens, S.
    Chen, C-I.
    Schmults, C. D.
    Pavlick, A. C.
    Guminski, A.
    Hauschild, A.
    Chen, Z.
    Mastey, V.
    Bury, D.
    Chang, A. L. S.
    Rabinowits, G.
    Ibrahim, S. F.
    Fury, M. G.
    Li, S.
    Sasane, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S738 - S738
  • [36] Efficacy of pembrolizumab in patients with cutaneous aquamous cell carcinoma
    Ferrarotto, Renata
    Glisson, Bonnie
    Blumenschein, George
    Hong, David
    Piha-Paul, Sarina
    Jain, Dipti
    Alshawa, Anas
    Painter, Jeane
    Hess, Kenneth
    Colen, Rivka
    Bernatchez, Chantale
    Lu, Charles
    Stephen, Bettzy
    Tapia, Coya
    Mendoza, Tito
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [37] Phase II postoperative adjuvant radiotherapy and erlotinib in patients with stage III cutaneous squamous cell carcinoma
    Spencer, S.
    Carroll, W.
    Nebell, L.
    Meredith, R.
    Desmond, R.
    Magnuson, J.
    Rosenthal, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma
    Foote, M. C.
    McGrath, M.
    Guminski, A.
    Hughes, B. G. M.
    Meakin, J.
    Thomson, D.
    Zarate, D.
    Simpson, F.
    Porceddu, S. V.
    ANNALS OF ONCOLOGY, 2014, 25 (10) : 2047 - 2052
  • [39] Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
    Saint-Ghislain, M.
    Abdeddaim, C.
    Chaltiel, R.
    Cousin, S.
    Gomez-Roca, C. A.
    Borel, C.
    Ghiringhelli, F.
    Vansteene, D.
    Bigot, F.
    Jeannot, E.
    Rocco, E. Guerini
    Frige, G.
    Mazzarella, L.
    Francisco, M.
    Legrand, F.
    Jimenez, M.
    Halladjian, M.
    Kamal, M.
    Cabarrou, B.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S518 - S518
  • [40] Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma - subgroup analysis of the PEVOsq basket trial
    Le Tourneau, C.
    Ghiringhelli, F.
    Saada, E. B.
    Chaltiel, R.
    Vansteene, D.
    Durando, X.
    You, B.
    Borel, C.
    Bigot, F.
    Abdeddaim, C.
    Marret, G.
    Jeannot, E.
    Rocco, E. Guerini
    Frige, G.
    Servant, N.
    Dupain, C.
    Kamal, M.
    Legrand, F.
    Jimenez, M.
    Filleron, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S583 - S583
12345